EPO vs IGF-1 LR3
A side-by-side research comparison of EPO and IGF-1 LR3 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | EPO | IGF-1 LR3 |
|---|---|---|
| Full name | Erythropoietin (EPO) | Insulin-like Growth Factor-1 Long R3 |
| Category | Muscle Growth | Muscle Growth |
| Status | FDA-approved drug (prescription) | Research compound |
| Mechanism | Binds erythropoietin receptors on bone marrow progenitor cells, stimulating proliferation and maturation of red blood cells. More red cells raise oxygen-carrying capacity, but also thicken the blood. | Activates IGF-1R while evading IGFBP sequestration. Triggers PI3K/Akt/mTOR for protein synthesis, satellite cell proliferation, and amino acid uptake into muscle. |
| Molecular weight | ~34 kDa (glycosylated) | 9,111 Da |
| Half-life | ~4-13 hours (varies by formulation) | 20-30 hours (vs 15 min native) |
| Bioavailability | Subcutaneous or intravenous injection | High (SubQ/IM) |
| Typical dose | Prescription-only, condition-specific | 20-50 mcg |
| Frequency | Per medical protocol | Daily (post-workout) |
| Route | Subcutaneous or IV injection | Subcutaneous or intramuscular injection |
EPO reported benefits
- Increases red blood cell production
- Treats anemia (medical use)
- Raises oxygen-carrying capacity
IGF-1 LR3 reported benefits
- Potent anabolic effects
- Hyperplasia (new muscle cells)
- Extended half-life
- Enhanced recovery
- Improved nutrient partitioning
- Satellite cell activation
Related comparisons
Research and educational reference only. Not medical advice.